BofA raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $225 from $217 and keeps a Buy rating on the shares. Following the recent approval of Modeyso for treatment of an ultra-rare brain tumor, the firm spoke with two key opinion leaders, who offered “positive feedback” on Modeyso uptake and the odds of success for the confirmatory Phase 3 study, the analyst tells investors. While Modeyso’s lead U.S. indication for the recurrent setting is likely to be niche, the firm came away from the expert calls “more assured” about the prospects for the confirmatory ACTION trial, which could boost peak U.S. sales to greater than $400M, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Promising Market Potential for Jazz Pharmaceuticals’ Modeyso Drives Buy Rating
- Jazz Pharmaceuticals’ Earnings Call: Growth Amid Challenges
- Jazz Pharmaceuticals confirms FDA approval of Modeyso
- Jazz Pharmaceuticals wins accelerated FDA approval of dordaviprone
- Positive Growth Outlook for Jazz Pharmaceuticals Amid Strategic Developments and Promising Drug Pipeline